Condition: Diabetic Foot Ulcer · Venous Leg Ulcer · Sponsor: MiMedx Group, Inc.
The purpose of this survey is to observe the efficacy and safety of EPIFIX® dehydrated human amnion/chorion membrane (DHACM) for the treatment of intractable diabetic foot ulcers or venous leg ulcers.
This description comes directly from the study's public registry record.
Chief Medical Officer · 770-651-9100 · CTInquiries@mimedx.com
Always discuss trial participation with your own doctor first.
| Kobe University Hospital | Kobe, Hyōgo, Japan | Recruiting |
| Saitame Medical University Hospital | Iruma-gun, Saitama, Japan | Recruiting |
| Juntendo University Hospital | Bunkyō-Ku, Tokyo, Japan | Recruiting |
| Kyorin University Hospital | Mitaka-shi, Tokyo, Japan | Recruiting |
| Tokyo Medical University Hospital | Shinjuku-Ku, Tokyo, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06236750